All News

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Ian Flinn and Dr. Saad Usmani how the new coronavirus has affected stem cell transplantations as well as the management of chronic lymphocytic leukemia and myeloma clinical trials.

An imaging technique known as PSMA PET/CT can detect disease spread at diagnosis more effectively than conventional scans, helping doctors to prescribe appropriate treatments.

International Nonprofit Provides 126K+ Swabs Globally to Help Fight Virus

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.

Having cancer is hard enough, but "orphan diseases" can add another degree of division and its own form of social distancing.

Surviving cancer teaches us emotional resilience, making even a frightening pandemic something we can decide we can navigate.

The new normal is HARD and SCARY, even for a cancer fighter who's become all too familiar with those conditions over the years.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.

The Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous form of Darzalex, for adults with newly diagnosed or relapsed/refractory multiple myeloma.

One survivor leans on their experiences from fighting cancer to find the strength to pivot during the time of the COVID-19 pandemic.

From a renowned actor passing away after a rare neuroendocrine cancer diagnosis and years of treatment to LUNGevity announcing a new fund for patients with lung cancer in need of financial assistance during the COVID-19 pandemic, here’s what’s happening in the cancer space this week.

Each one of us is unique and that includes our cancer journey. We cannot compare ourselves to anyone else!

Here is a list of the recent trial initiations that occurred within the cancer space in April.

Dr. Andrew Coveler discusses the use of electric fields to disrupt cell division during pancreatic cancer treatment.

The Pancreatic Cancer Collective, a collaboration between the Lustgarten Foundation and Stand Up To Cancer, announced four recipients of further funding to develop new treatments for pancreatic cancer.

Learn what you should do to prevent the spread of COVID-19, especially if you have a weakened immune system from pancreatic cancer treatment.

Pancreatic cancer experts discuss treatment during the COVID-19 pandemic, along with other important issues for patients.

A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.

The Food and Drug Administration has approved the use of Zejula as a frontline maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who responded to chemotherapy.

Part of the prognosis is often what the patient brings to it, the journey ahead of them that only they can travel.

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

A newly diagnosed patient talks about her experience of being diagnosed with breast cancer amidst the COVID-19 pandemic.

After treatment ends, survivors are left to navigate a new life but that life comes with its new emotions and reactions to the world around us.

The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one expert.

Dr. Omid Hamid discusses combining targeted drugs and immunotherapy, the role of surgery and ongoing research efforts in melanoma.

During hard times, we must hold on to what we know well.

Dr. Richard Pazdur, director of the Food and Drug Administration’s Oncology Center of Excellence, has noted that the agency is committed to expediting oncology drug development despite the challenges posed by the COVID-19 pandemic.

Purpose directs the energy outward, and when tied to a beneficent cause, the experience is that of being connected to a deeper source— worry for self becomes compassion for others.

How can we relax and move forward when cancer and COVID-19 take up so much of our day?

The Food and Drug Administration approved the targeted therapy Tukysa as part of a drug combination to treat HER2-positive breast cancer. Here’s what you need to know.